View Post

Pyrotinib plus capecitabine versus lapatinib plus capecitabine for the treatment of HER2-positive metastatic breast cancer (PHOEBE)

In Clinical Trials by Barbara Jacoby

From: thelancet.com A multicentre, open-label, randomised, controlled, phase 3 trial Background Despite therapeutic advances in HER2-positive metastatic breast cancer, resistance to trastuzumab inevitably develops. In the PHOEBE study, we aimed to assess the efficacy and safety of pyrotinib (an irreversible pan-HER inhibitor) plus capecitabine after previous trastuzumab. Methods This is an open-label, randomised, controlled, phase 3 trial done at 29 …

View Post

Changing the doses to treat aggressive breast cancer

In In The News by Barbara Jacoby

By: Jim Mertens From: wqad.com Is it possible to get the benefits of chemo without the side effects? Researchers are looking into a new treatment for an aggressive form of breast cancer that is showing some promise. Almost 300,000 American women will hear the words, “You have breast cancer” this year alone. One in four of those breast cancer diagnosis …

View Post

Many supposed breast cancer risk genes don’t raise risk, studies find

In In The News by Barbara Jacoby

By: Marie McCullough, The Philadelphia Inquirer From: medicalxpress.com In the quarter century since the watershed discovery of BRCA1 and BRCA2, dozens of other genes have been implicated in hereditary breast cancer. A slew of commercial tests are now available that look for mutations in those breast cancer “predisposition genes” to help guide health-care decisions. The thing is, some of the …

View Post

Study Looks at T2DM, Metformin Use, and Breast Cancer Risk

In Clinical Trials by Barbara Jacoby

From: healthday.com Links between T2DM with metformin use and breast cancer risk appear to be affected by hormone receptor status The risks for breast cancer in women with type 2 diabetes (T2D) may be influenced by long-term metformin use, according to a study published online Jan. 28 in the Annals of Oncology. Yong-Moon Mark Park, M.D., Ph.D., from the National …

View Post

HER2-Positive Breast Cancer Survival Rates and Other Statistics

In In The News by Barbara Jacoby

From: healthline.com Breast cancer isn’t a single disease. It’s actually a group of diseases. When diagnosing breast cancer, one of the first steps doctors take is identifying the type of breast cancer. The type provides key information about how the cancer may behave. About 13 percent of women in the United States will develop invasive breast cancer. Anyone can develop …

View Post

Brooklyn ImmunoTherapeutics Announces Initiation of Phase 2 Trial of IRX-2 in Combination with Pembrolizumab and Chemotherapy in Triple Negative Breast Cancer

In Clinical Trials by Barbara Jacoby

By: Brooklyn ImmunoTherapeutics From: businesswire.com Brooklyn ImmunoTherapeutics LLC (“Brooklyn”), a biopharmaceutical company focused on exploring the role that cytokine-based therapy can have in treating patients with cancer, today announced the initiation of an open-label Phase 2 clinical trial of IRX-2 in combination with pembrolizumab (Keytruda®) and chemotherapy in triple negative breast cancer (TNBC). The trial will be conducted at the …

View Post

Breath holds protect the heart during proton therapy for breast cancer

In Clinical Trials by Barbara Jacoby

By: Tami Freeman From: physicsworld.com Radiation therapy plays an integral role in the management of breast cancer. Following breast-conserving surgery, in which the tumour is removed while leaving as much healthy breast tissue as possible, irradiation of the whole breast is a standard follow-up procedure. In some cases, irradiation of regional lymph nodes and/or a boost to the tumour cavity …

View Post

Breast cancer death rates stop declining in younger women

In In The News by Barbara Jacoby

Source: Radiological Society of North America From: eurekalert.org Breast cancer death rates have stopped declining for women in the U.S. younger than age 40, ending a trend that existed from 1987 to 2010, according to a new study in Radiology. Researchers expressed hope that the findings would raise awareness of breast cancer in younger women and spur research into the …

View Post

Drug is promising against pancreatic and breast cancers

In Clinical Trials by Barbara Jacoby

Source: Georgia State University From: eurekalert.org ProAgio, created from a human protein, targets the cell surface receptor integrin αVβ?, which is expressed on cancer-associated fibroblasts ProAgio, a drug developed by Georgia State University biology professor Zhi-Ren Liu and his team, is effective at treating pancreatic cancer and prolonging survival in mice, according to a study published in the journal Cellular …